BioScrip Reschedules Release of Fourth Quarter and Full Year 2018 Financial Results and Conference Call
March 13 2019 - 10:11PM
BioScrip, Inc. (NASDAQ: BIOS) ("BioScrip" or the "Company"), the
largest independent national provider of infusion and home care
management solutions, today announced that the Company has
rescheduled the release of its fourth quarter and full year 2018
financial results from Thursday, March 14, 2019 to Friday, March
15, 2019, before the opening of the U.S. financial markets.
The Company will also be filing its Form 10-K annual report with
the U.S. Securities and Exchange Commission on Friday, March 15,
2019.
Daniel E. Greenleaf, President and Chief Executive Officer, and
Stephen Deitsch, Senior Vice President, Chief Financial Officer and
Treasurer, will host a conference call as follows:
Date |
March 15, 2019 |
Time |
9:00 a.m. ET |
Toll
free (U.S.) |
(877) 423-9820 |
International |
(201) 493-6749 |
Webcast (live and replay) |
https://78449.themediaframe.com/dataconf/productusers/bios/mediaframe/29020/indexl.html |
|
Or |
|
www.bioscrip.com |
The online replay will be available within two hours of the
call’s completion in the Investor Relations section of BioScrip’s
web site at: www.bioscrip.com.
About BioScrip, Inc.BioScrip, Inc. is the
largest independent national provider of infusion and home care
management solutions, with approximately 2,100 teammates and nearly
70 service locations across the U.S. BioScrip partners with
physicians, hospital systems, payors, pharmaceutical manufacturers
and skilled nursing facilities to provide patients access to
post-acute care services. BioScrip operates with a commitment to
bring customer-focused pharmacy and related healthcare infusion
therapy services into the home or alternate-site setting. By
collaborating with the full spectrum of healthcare professionals
and the patient, BioScrip provides cost-effective care that is
driven by clinical excellence, customer service, and values that
promote positive outcomes and an enhanced quality of life for those
it serves.
Investor
Contacts |
|
Stephen Deitsch |
Kalle Ahl, CFA |
Chief Financial Officer
& Treasurer |
The Equity Group |
T: (720)
697-5200 |
T: (212) 836-9614 |
stephen.deitsch@bioscrip.com |
kahl@equityny.com |
BioPlus Acquisition (NASDAQ:BIOS)
Historical Stock Chart
From Mar 2024 to Apr 2024
BioPlus Acquisition (NASDAQ:BIOS)
Historical Stock Chart
From Apr 2023 to Apr 2024